Baker Bros Advisors Lp decreased its stake in Chemocentryx Inc. (CCXI) by 50% based on its latest 2018Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 207,000 shares as the company’s stock rose 6.99% with the market. The hedge fund held 207,029 shares of the health care company at the end of 2018Q4, valued at $2.26 million, down from 414,029 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Chemocentryx Inc. for a number of months, seems to be less bullish one the $547.77M market cap company. The stock increased 1.96% or $0.2 during the last trading session, reaching $10.42. About 85,927 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 15, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Rhenman & Partners Asset Management Ab decreased its stake in Alkermes Plc (ALKS) by 42.18% based on its latest 2018Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 127,211 shares as the company’s stock declined 8.22% while stock markets rallied. The institutional investor held 174,399 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $5.15 million, down from 301,610 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Alkermes Plc for a number of months, seems to be less bullish one the $5.23B market cap company. The stock increased 0.96% or $0.32 during the last trading session, reaching $33.49. About 159,676 shares traded. Alkermes plc (NASDAQ:ALKS) has declined 40.70% since March 15, 2018 and is downtrending. It has underperformed by 45.07% the S&P500. Some Historical ALKS News: 26/04/2018 – Alkermes 1Q Loss $62.5M; 14/05/2018 – Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare Conference; 30/04/2018 – Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting; 02/05/2018 – Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference; 02/04/2018 – ALKERMES PLC SAYS “STRONGLY DISAGREES WITH FDA’S CONCLUSIONS AND PLANS TO APPEAL FDA’S DECISION”; 02/04/2018 – FDA rejects application to review Alkermes’ depression treatment; 02/04/2018 – $ALKS -20% plus ; close to $2B; 16/04/2018 – STAT Plus: Alkermes’s depression drug is back on track after an FDA ‘misunderstanding’; 29/03/2018 – ALKERMES SAYS AMENDMENT PROVIDES FOR NEW CLASS OF REPLACEMENT TERM LOANS OF $284.3 MLN MATURING ON MARCH 26, 2023 – SEC FILING; 03/05/2018 – ALKERMES TO DISCUSS ALKS 3831 DEVELOPMENT PROGRAM MAY 10
Since October 16, 2018, it had 0 buys, and 8 sales for $87.64 million activity. Cappel Markus J. sold 30,237 shares worth $332,779. Schall Thomas J. sold $447,092 worth of stock. On Tuesday, October 16 the insider GLAXOSMITHKLINE PLC sold $85.85 million.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights – Nasdaq” on March 11, 2019, also Globenewswire.com with their article: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” published on September 26, 2018, Seekingalpha.com published: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” on September 28, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” published on March 11, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” with publication date: March 11, 2019.
Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It fall, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Morgan Stanley has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 39,571 shares. 16,500 are owned by Dekabank Deutsche Girozentrale. 156,559 are owned by Alps Advsrs. Franklin Resource, California-based fund reported 1.38M shares. Nantahala Capital Mgmt Limited Liability Company, Connecticut-based fund reported 623,338 shares. Tower Research Ltd Com (Trc) holds 257 shares. Bnp Paribas Arbitrage owns 10 shares or 0% of their US portfolio. Group Incorporated One Trading Lp stated it has 13,165 shares or 0% of all its holdings. State Street invested in 487,355 shares or 0% of the stock. Blackrock Incorporated reported 2.73 million shares or 0% of all its holdings. Citadel Advisors Ltd Liability Corp invested in 0% or 19,773 shares. Invesco Ltd accumulated 0% or 143,834 shares. State Of Wisconsin Invest Board owns 23,200 shares. 37,000 were accumulated by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta. Sectoral Asset Incorporated holds 0.03% or 17,811 shares.
Baker Bros Advisors Lp, which manages about $8.20 billion and $12.21 billion US Long portfolio, upped its stake in Krystal Biotech Inc. by 670,000 shares to 784,674 shares, valued at $16.31M in 2018Q4, according to the filing. It also increased its holding in Aeglea Biotherapeutics Inc. by 325,732 shares in the quarter, for a total of 1.71 million shares, and has risen its stake in Biomarin Pharmaceutical Inc. (NASDAQ:BMRN).
Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on April, 25. They expect $-0.38 EPS, down 90.00% or $0.18 from last year’s $-0.2 per share. After $0.17 actual EPS reported by Alkermes plc for the previous quarter, Wall Street now forecasts -323.53% negative EPS growth.
More notable recent Alkermes plc (NASDAQ:ALKS) news were published by: Seekingalpha.com which released: “Alkermes cut to Sell at Goldman – Seeking Alpha” on December 18, 2018, also Nasdaq.com with their article: “Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates – Nasdaq” published on February 15, 2019, Nasdaq.com published: “Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates – Nasdaq” on February 27, 2019. More interesting news about Alkermes plc (NASDAQ:ALKS) were released by: Globenewswire.com and their article: “Alkermes Public Limited Company Reminder: Pawar Law Reminds of Important February 25, 2019 Lead Plaintiff Deadline in Class Action â€“ ALKS – GlobeNewswire” published on February 22, 2019 as well as Globenewswire.com‘s news article titled: “Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide Inc. (YRCW): Bronstein, Gewirtz & Grossman, LLC Class Action Update – GlobeNewswire” with publication date: February 19, 2019.
Rhenman & Partners Asset Management Ab, which manages about $874.81M US Long portfolio, upped its stake in Diplomat Pharmacy Inc Reg (NYSE:DPLO) by 28,994 shares to 1.20M shares, valued at $16.20 million in 2018Q4, according to the filing. It also increased its holding in Allergan Plc by 28,555 shares in the quarter, for a total of 98,600 shares, and has risen its stake in Celgene Corp (NASDAQ:CELG).